Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria (pages 2999–3006)
Nils Kroeger, Wanling Xie, Jae-Lyn Lee, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Sandy Srinivas, Ulka N. Vaishamayan, Sun-Young Rha, Sumanta K. Pal, Takeshi Yuasa, Frede Donskov, Neeraj Agarwal, Christian K. Kollmannsberger, Min-Han Tan, Scott A. North, Brian I. Rini, Toni K. Choueiri and Daniel Y.C. Heng
Article first published online: 21 MAY 2013 | DOI: 10.1002/cncr.28151
The International mRCC Database Consortium risk model is a reliable prognostication tool that can be employed to prognosticate overall survival in non–clear cell renal cell carcinoma (nccRCC) for patient counseling and clinical trials design. The survival outcome for the majority of nccRCC patients remains lower than their clear-cell counterparts.